Cowen & Co. analyst Boris Peaker maintained a Hold rating on Seattle Genetics (NASDAQ: SGEN) today and set a price target of $71. The company’s shares opened today at $54.05.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.6% and a 39.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $83.89, which is a 55.2% upside from current levels. In a report issued on October 22, Oppenheimer also assigned a Hold rating to the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $84.37 and a one-year low of $47.75. Currently, Seattle Genetics has an average volume of 880.1K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Last month, Vaughn Himes, the CTO of SGEN sold 5,000 shares for a total of $384,962.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
